Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease

NCT06878430 | Not Yet Recruiting

• 2 other identifiers: AC25041HIPS/23/02
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of the DISCOVER study is to pilot acceptable approaches to people with covert cerebrovascular disease (CCD) and their follow-up. This is the first step in designing efficient randomised trials of treatments to reduce the risk of stroke or dementia in people with CCD.

Conditions

Covert Cerebrovascular Disease

Keywords

ccd

Outcome Measures

Primary Outcomes (4)

• Functional scores

  The investigators will measure day-to-day function with the Bristol Activities of Daily Living Scale, which is a 20-item assessment of daily living abilities for dementia. Each activity has 5 statement options (a - e) which refer to a different level of ability.

  At 3, 6 and 12 months following enrolment

• Cognitive scores

  The investigators will measure concerns or anxiety about covert cerebrovascular disease using the Montreal Cognitive Assessment. It is a 10-minute test that assesses seven areas of cognition for a total possible score of 30 points. A score of 25 or less is indicative of cognitive impairment.

  At 3, 6 and 12 months following enrolment

• Speech samples

  Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No. 310885).

  At 3, 6 and 12 months following enrolment

• Vascular events

  At each assessment the investigators will ask about dementia, mild cognitive impairment and stroke symptoms.

  At 3, 6 and 12 months following enrolment

Interventions

Functional and Cognitive scores OTHER

We will collect information about prior neurological symptoms, including prior symptoms suggestive of TIA or stroke, cognitive or motor symptoms, blood pressure and other known vascular risk factors, medicines, frailty, functional status, education, and employment status We will collect a baseline validated function and cognitive score, and take a sample of speech. Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No. 310885).

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

People aged 65 years or older living in Scotland, UK

You may qualify if:

• People who, at the time the letter is prepared or are identified by a clinician
• Age ≥ 65 years
• Have no known history of:
• Stroke or TIA
• Dementia
• Parkinson's disease
• Multiple sclerosis
• Metastatic cancer (or non-meningioma brain tumour).
• A CT or MRI scan report ≤5 years before study start date with of one or more of:
• Cerebral small vessel disease
• Deep old ischaemic stroke
• Cortical old ischaemic stroke

You may not qualify if:

• Text of brain scan report unreadable
• Do not consent to take part in study procedures
• Unable to consent
• Unable to communicate by email, letter or telephone through language, speech disability or lack of address
• Unlikely to survive one year past enrolment in judgement of the study investigator

Sponsors & Collaborators

• University of Edinburgh: lead
• NHS Lothian: collaborator

MeSH Terms

Conditions

Myopathy, Central Core

Interventions

Functional Status

Condition Hierarchy (Ancestors)

Myopathies, Structural, Congenital; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Activities of Daily Living; Rehabilitation; Health Services; Health Care Facilities Workforce and Services; Health Status; Demography; Epidemiologic Measurements; Public Health; Environment and Public Health

Central Study Contacts

William Whiteley

CONTACT

+44(131) 4659602; william.whiteley@ed.ac.uk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 6, 2025
• First Posted: March 17, 2025
• Study Start: May 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): June 1, 2027
• Last Updated: April 16, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share